Publications + Posters

TNG908 is an MTAP^null-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies

USP1 inhibitor synthetic lethality in BRCA1/2 mutant cancer is driven by PCNA ubiquitination

UMIBB: A novel nonparametric Bayesian method improves robustness and sensitivity of analysis in pooled CRISPR Cas9 screens leveraging unique molecular identifiers

Evidence for synergy between TNG908, an MTAP^null-selective PRMT5 inhibitor, and sotorasib in an MTAP^null/KRASG12C xenograft model

TNG908 is an MTAP^null-selective PRMT5 inhibitor that drives tumor regression in MTAP-deleted xenograft models across histologies

VRK1 is a novel synthetic lethal target in VRK2-methylated glioblastoma

CRISPR screens identify sensitizers to trametinib in KRAS mutant cancer cell lines

Loss of HS2ST1 cooperates with MAPK inhibition to impair growth of mesenchymal KRAS mutant NSCLC

Isogenic CRISPR anchor screens identified actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant cancer

In vivo CRISPR screen identifies tumor suppressors as drivers of tumor cell-intrinsic immune evasion

Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency-guided First-in-Human Studies

Synthetic lethality as an engine for cancer drug target discovery

EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer